Medra closed a $52M Series A to expand robotic labs and ‘Physical AI Scientists’ that link AI predictions to real experiments, speeding drug discovery for patients.
Medra Raises $52M to Scale ‘Physical AI Scientists’ and Robotic Drug Discovery Read More »
AI is shortening drug discovery timelines by improving target identification, compound optimization and trial matching. What this means for patients and pharma.
How AI Is Accelerating Drug Discovery: Faster Paths from Target to Trial Read More »
Discover how AI and explainable models like Ignota Labs’ SAFEPATH identify toxicity mechanisms to repurpose shelved drugs, cutting costs and carbon footprints.
AI Rescues Failed Medicines: How Ignota Labs’ SAFEPATH Is Reclaiming Drug Value Read More »
Explore how AI platforms such as MMV’s MAIP and dd4gh speed malaria drug discovery and make advanced tools accessible to scientists in low- and middle-income countries.
How AI Is Accelerating and Democratizing Drug Discovery for Malaria Read More »
Explore how generative AI and automation are transforming drug discovery with faster design, synthesis, and testing cycles. Learn about business impact and future prospects.
AI and Automation: The New Reality in Drug Discovery Read More »
Discover how AI is transforming drug development, closing the divide between large pharmaceutical firms and biotech startups through faster discovery, smarter trials, and innovative collaborations.
AI Reshapes Drug Development by Bridging the Gap Between Big Pharma and Biotech Read More »
Explore how practical AI applications, data integrity, and human-relevant biological models are transforming drug discovery into a precise and reliable process.
Practical AI Drives the Future of Drug Discovery Read More »
Discover how Expedition Medicines, backed by Flagship Pioneering and partnered with Pfizer, uses an AI-driven quantum chemistry platform to create novel therapies for undruggable proteins in oncology and immunology.
Flagship Pioneering introduces Expedition Medicines, backed by $50M funding, employing AI and covalent chemistry to develop new treatments for cancer and immune diseases with Pfizer collaboration.
Explore how chemistry-aware AI, exemplified by Iktos’s Makya platform, is overcoming synthesis challenges in AI drug discovery to accelerate small molecule design and improve drug development.
